Apnimed has acquired the intellectual property and exclusive worldwide rights from European pharma company Desitin Arzneimittel for developing and commercialising a differentiated carbonic anhydrase inhibitor, sulthiame, targeting sleep apnoea and sleep-related breathing conditions.
Tempus AI has entered into strategic partnerships with AstraZeneca and Pathos AI to develop a multimodal foundation model in oncology.
The National Institute for Health and Care Excellence (NICE) has issued final guidance endorsing Pharming Group’s Joenja (leniolisib) for use and reimbursement in the National Health Service (NHS) in England and Wales.
Ensem Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application for ETX-636.
Viatris has submitted applications to Japan's Ministry of Health, Labor and Welfare (MHLW) for the approval of Effexor SR Capsules (venlafaxine hydrochloride) to treat adults with generalised anxiety disorder (GAD).
The US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for CLD-201, an allogeneic stem cell-based immunotherapy developed by Calidi Biotherapeutics, set to advance into clinical development for solid tumours.
US-based biotechnology company Glycomine has secured $115m in Series C funding to progress the mannose-1-phosphate replacement therapy GLM101 into a randomised Phase IIb trial.
Norgine has entered into a definitive agreement to acquire Theravia, a pharma laboratory that specialises in rare and debilitating condition treatments.
INmune Bio has collaborated with the Cell and Gene Therapy Catapult (CGT Catapult) to set up large-scale manufacturing for its cell therapy platforms.
Nona Biosciences has entered into a research collaboration with Atossa Therapeutics for the discovery of next-generation antibody therapies for treating breast cancer.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.